Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 6,732 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Medication Management Clear all
Completed Not applicable Interventional

Contingency Management for Persons With Severe Mental Illness

NCT01478815
View directory record Official record
Conditions
Substance Abuse
Interventions
contingency management, Standard Care
Behavioral · Other
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New Britain, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 21, 2026, 1:20 AM EDT
Active, not recruiting Phase 2 Interventional

Rapid Administration Pilot for Infusing Dinutuximab

NCT05421897
View directory record Official record
Conditions
Neuroblastoma
Interventions
Dinutuximab with Chemotherapy
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 21, 2026, 1:20 AM EDT
Withdrawn Phase 4 Interventional

Treating Nocturnal Hypertension and Nocturia in African American Men

NCT03319823
View directory record Official record
Conditions
High Blood Pressure
Interventions
Thiazide Treatment Group, Intensified Thiazide Treatment Group, Combination Medication Treatment Group
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
35 Years to 59 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 21, 2026, 1:20 AM EDT
Completed Not applicable Interventional

Home Blood Pressure Monitoring Project

NCT01162759
View directory record Official record
Conditions
Hypertension
Interventions
Home Blood Pressure Monitoring
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 85 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 6, 2012 · Synced Oct 21, 2026, 1:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354

NCT00638989
View directory record Official record
Conditions
Asthma, Healthy
Interventions
CAT-354 150 mg (intravenous), CAT-354 150 mg (subcutaneous), CAT-354 300 mg (subcutaneous)
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 21, 2026, 1:20 AM EDT
Terminated Not applicable Interventional

Primary Care-Based Physical Activity for Diabetic Latinas

NCT02741050
View directory record Official record
Conditions
Diabetes, Sedentary Lifestyle
Interventions
Tailored Physical Activity Intervention, Standard of Care
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 21, 2026, 1:20 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis

NCT00705159
View directory record Official record
Conditions
Conjunctivitis
Interventions
loteprednol etabonate and tobramycin, loteprednol etabonate, Tobramycin, Vehicle of Zylet
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
1 Week to 6 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 21, 2026, 1:20 AM EDT
Completed Not applicable Interventional

Improving Fatigue: A Pilot Study of Acupuncture and Patient Education for Breast Cancer Survivors

NCT00646633
View directory record Official record
Conditions
Fatigue
Interventions
Acupuncture and patient education
Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2016 · Synced Oct 21, 2026, 1:20 AM EDT
Completed Not applicable Interventional

The eyeGuide: Improving Glaucoma Self-management With a Personalized Behavior Change Program

NCT03159247
View directory record Official record
Conditions
Medication Adherence, Glaucoma
Interventions
eyeGuide
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
40 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 21, 2026, 1:20 AM EDT
Completed Not applicable Interventional

Juvenile Justice Girls Randomized Control Trial: Young Adult Follow-up

NCT01341626
View directory record Official record
Conditions
Delinquency, Drug Use
Interventions
Treatment Foster Care (TFCO), Group Care
Behavioral
Lead sponsor
Oregon Social Learning Center
Other
Eligibility
13 Years to 18 Years · Female only
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2016
U.S. locations
2
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 21, 2026, 1:20 AM EDT
Completed Phase 2 Interventional Results available

A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)

NCT00685360
View directory record Official record
Conditions
Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant, Extensively Drug-Resistant Tuberculosis
Interventions
Delamanid, Optimized Background Regimen (OBR), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Oct 21, 2026, 1:20 AM EDT
Completed Phase 2 Interventional Results available

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

NCT00394082
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
ABI-007, Bevacizumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Melbourne, Florida • Ocoee, Florida • Niles, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 21, 2026, 1:20 AM EDT
Completed Phase 4 Interventional

Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression

NCT05615948
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Analgesia, Ketamine, Peripheral Nervous System Agents, Central Nervous System Depressants, Neurotransmitter Agents, Anti-Inflammatory Agents, Physiological Effects of Drugs, Sensory System Agents, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal, Depressive Symptoms
Interventions
VTS-K
Drug
Lead sponsor
Theresa Jacob, PhD, MPH
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 21, 2026, 1:20 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

NCT04052555
View directory record Official record
Conditions
Bilateral Breast Carcinoma, HER2-Negative Breast Carcinoma, Localized Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions
Berzosertib, Biospecimen Collection, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
14
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 21, 2026, 1:20 AM EDT
Completed Not applicable Interventional Results available

Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases

NCT01528878
View directory record Official record
Conditions
Liver Neoplasms, Colonic Neoplasms, Metastatic Cancer to Liver
Interventions
Stereotactic Radiosurgery using the CyberKnife System.
Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 21, 2026, 1:20 AM EDT
Completed Not applicable Interventional

Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

NCT00000708
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Flucytosine, Fluconazole, Amphotericin B
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Miami, Florida • New Orleans, Louisiana • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 21, 2026, 1:20 AM EDT
Completed Phase 2 Interventional

PS-341 in Treating Patients With Metastatic Kidney Cancer

NCT00025376
View directory record Official record
Conditions
Kidney Cancer
Interventions
PS-341, Tumor Biopsy
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
10
States / cities
Chicago, Illinois • Decatur, Illinois • Harvey, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 21, 2026, 1:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Parenting Skills Intervention in Improving Medication Adherence in Pediatric Cancer Patients

NCT03895918
View directory record Official record
Conditions
Guardian, Hematologic and Lymphocytic Disorder, Malignant Neoplasm, Parent
Interventions
Educational Activity, Patient Monitoring, Questionnaire Administration
Other · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 21, 2026, 1:20 AM EDT
Completed Phase 1Phase 2 Interventional

Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack

NCT00093197
View directory record Official record
Conditions
Myocardial Infarction
Interventions
KAI-9803 for Injection, Placebo
Drug
Lead sponsor
KAI Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2011 · Synced Oct 21, 2026, 1:20 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of [14C]-LY3023703 in Healthy Participants

NCT01965782
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[^14C]-LY3023703
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 21, 2026, 1:20 AM EDT
Completed Phase 4 Interventional Results available

Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking

NCT02995915
View directory record Official record
Conditions
Smoking Cessation, Alcohol Drinking
Interventions
Nicotine Replacement Therapy, Bupropion, Cognitive Behavioral Treatment, Mobile Contingency Management, Mobile Monitoring
Other · Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 21, 2026, 1:20 AM EDT
Completed Not applicable Interventional Results available

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

NCT01701674
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Ipilimumab, Tumor Infiltrating Lymphocytes (TIL), Administration of Lymphodepletion, Cyclophosphamide as Part of Lymphodepletion, Fludarabine as Part of Lymphodepletion, High Dose IL-2, Adoptive Cell Therapy with TIL
Drug · Procedure · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 21, 2026, 1:20 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)

NCT07477418
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms
Interventions
Gemcitabine Delivered by Transarterial Microperfusion
Combination Product
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 21, 2026, 1:20 AM EDT
Completed Not applicable Interventional Results available

Minocycline in the Treatment of Angelman Syndrome

NCT01531582
View directory record Official record
Conditions
Angelman Syndrome
Interventions
minocycline
Drug
Lead sponsor
University of South Florida
Other
Eligibility
4 Years to 12 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 21, 2026, 1:20 AM EDT